Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Protein C Vapor Heated · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Protein C Concentrate (Human) Vapor Heated | DRUG | - |
Inclusion Criteria: * Newborn subjects \<= 6 months of age: diagnosis of severe congenital protein C deficiency, with documented functional protein C level \< 20%. If a genetic diagnosis is not available prior to initiation of Protein C Concentrate treatment, a documented family history of protein ...
Protein C Vapor Heated is used for the treatment of Protein C Deficiency, a rare genetic disorder that increases the risk of blood clots. It is being developed as a therapy to address this condition in the hematology therapeutic area.
Protein C Vapor Heated is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research to evaluate the drug's efficacy and safety for patients with Protein C Deficiency.
Protein C Vapor Heated is in Phase 2 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for its safety and effectiveness in treating Protein C Deficiency.
Protein C Vapor Heated has one completed Phase 2 clinical trial, identified as NCT00157118. This study, titled 'Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency,' enrolled 18 participants in the United States and was uncontrolled.
Yes, Protein C Vapor Heated is also known as Protein C Concentrate. The clinical trial NCT00157118 refers to the drug as 'Protein C Concentrate,' and it is being studied for the treatment of severe congenital Protein C Deficiency.